The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Cellular Immunotherapy Market In 2026 And What Value Is Projected For 2030?
The cellular immunotherapy market has demonstrated rapid expansion in its size over recent years. It is projected to expand from $6.56 billion in 2025 to $7.48 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.1%. Historically, this growth has been fueled by the achievements of early CAR-T therapies, persistent unmet needs in oncology, an increase in research funding, timely regulatory approvals, and strong academic-industry collaboration.
The cellular immunotherapy market is poised for significant expansion in the coming years. It is projected to achieve a valuation of $12.5 billion by 2030, growing at a robust compound annual growth rate (CAGR) of 13.7%. This anticipated growth during the forecast period stems from factors such as the expansion into solid tumors, innovations in NK cell therapy, advancements in scalable manufacturing technologies, supportive regulatory frameworks, and increased investment in oncology. Prominent trends observed within this period include the rapid growth of CAR-T cell therapies, the broadening application of allogeneic cell therapies, their escalating utilization in hematologic malignancies, continuous advancements in T cell engineering, and a notable rise in clinical trial activity.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Cellular Immunotherapy Market?
The increasing incidence of cancer is projected to drive the expansion of the cellular immunotherapy market in the future. Cancer encompasses a range of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. This growing prevalence is primarily attributed to an aging demographic, various lifestyle elements, and advancements in screening and diagnostic methods. Furthermore, environmental influences and genetic susceptibilities contribute substantially to the escalating incidence figures. Cellular immunotherapy enhances the body’s immune reaction against cancer through precise targeting of tumor cells, thereby elevating survival prospects. When combined with other therapeutic interventions, this method holds the potential to reduce both the occurrence and reoccurrence of cancer. For example, data from March 2024, provided by MAC Clinical Research, a cancer research organization based in the UK, indicates that the projected number of individuals living with cancer in the United Kingdom is anticipated to rise from approximately 3 million presently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the expanding incidence of cancer is stimulating the development of the cellular immunotherapy market.
What Are The Key Segments Of The Cellular Immunotherapy Market?
The cellular immunotherapy market covered in this report is segmented –
1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy
2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications
3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications
Subsegments:
1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy
2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy
3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies
4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications
What Key Trends Are Influencing The Development Of The Cellular Immunotherapy Market?
Leading companies within the cellular immunotherapy sector are prioritizing technological progress, such as immunotherapy, with the goal of improving treatment effectiveness and broadening its applications. Their strategic emphasis includes personalized medical approaches, combination therapies, and scalable manufacturing processes designed to enhance patient outcomes. Immunotherapy is a medical intervention that utilizes the body’s own immune system to combat diseases, particularly cancer. This can involve either stimulating immune responses or administering targeted therapies to amplify immune activity against specific cells. For example, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, recognized CAR-T cell therapy as a groundbreaking cancer treatment. This therapy employs genetically engineered T cells to precisely target and eradicate cancer cells, thereby offering a tailored treatment method. It yields sustained remission rates, especially for refractory blood cancers, while simultaneously reducing harm to healthy tissues.
Who Are The Leading Companies Operating In The Cellular Immunotherapy Market?
Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation
Read the full cellular immunotherapy market report here:
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
What Are The Leading Geographic Regions In The Cellular Immunotherapy Market?
North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Cellular Immunotherapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp
Browse Through More Reports Similar to the Global Cellular Immunotherapy Market 2026, By The Business Research Company
Cellulars Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Cancer Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Allergy Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model